SINGAPORE · HEALTHCARE · MARKET SCAN

Singapore biomedical 2027 — contract research capacity and biotech IP commercialization

Executive summary

A disclosed 144,000-litre build-out lands into a tariff regime that reprices where a molecule is finished, while the research base converts into licensable assets at a fraction of the regional deal cadence. The 2027 window decides whether Singapore reads as a manufacturing address or an origination one.

The biomedical manufacturing cluster grew 16.2% year on year across the first ten months of 2025, with the pharmaceuticals segment up 122.9% in October alone on higher active-ingredient and biological output. Against a base of S$38.1 bn in 2023, we put 2025 output near S$43 bn and 2027 near S$49 bn.

The national drug-discovery platform has executed close to 20 licensing deals across 25 corporate partners and more than 70 academic institutions.

Report details

Published
2026-10-06
Pages
19
Format
PDF
Code
SG-HLT-XPL-D27-01
Market
Singapore
Industry
Healthcare
Year
2026

Table of contents · 11 sections

  1. 01 Singapore biomedical — capacity is arriving faster than deals
  2. 02 A narrow base, carrying a wide share of the economy
  3. 03 Four sites carry almost all of the new capacity
  4. 04 The duty attaches to the product, not the plant
  5. 05 Four operating models compete for the same regional mandate
  6. 06 Priced out on cost, competitive on the clock
  7. 07 A wide research base narrowing to a handful of partnered assets
  8. 08 Deal count is rising against a regional benchmark that moved first
  9. 09 Six mechanisms carry the commercialization system
  10. 10 2027 outlook: three paths for biomedical manufacturing output
  11. 11 Methodology & sources

The full report is available to subscribers and buyers. The executive summary above is free to read.

Key questions

How fast is Singapore's biomedical manufacturing cluster growing?

The biomedical manufacturing cluster grew 16.2% year on year in the first ten months of 2025 (EDB Mfg 2025), according to KIRA's 2026 market report.

Source: EDB Mfg 2025, 2025 · KIRA report: Singapore biomedical 2027 — contract research capacity and biotech IP commercialization

How much is Singapore committing to national R&D?

The RIE2030 Plan commits S$37 bn to national R&D, 32% above the prior plan, according to KIRA's 2026 market report.

Source: RIE2030 Plan, 2030 · KIRA report: Singapore biomedical 2027 — contract research capacity and biotech IP commercialization

How much drug-substance capacity is coming online in Singapore's biomedical sector?

Disclosed additions bring 144,000 litres of drug-substance capacity on line between 2024 and 2027 (WuXi Bio 2026; AbbVie 2024), according to KIRA's 2026 market report.

Source: WuXi Bio 2026, 2027 · KIRA report: Singapore biomedical 2027 — contract research capacity and biotech IP commercialization

How many Singapore-origin biomedical assets were licensed out in 2025?

8 Singapore-origin out-licensing transactions in 2025, up from three in 2022 (Kira estimates, according to KIRA's 2026 market report).

Source: Kira estimates, 2025 · KIRA report: Singapore biomedical 2027 — contract research capacity and biotech IP commercialization

How big is China's biopharma out-licensing market that Singapore assets are compared against?

Chinese biopharma out-licensing reached US$135.7 bn of deal value in 2025, the regional benchmark Singapore assets are priced against (China Lic 2026), according to KIRA's 2026 market report.

Source: China Lic 2026, 2025 · KIRA report: Singapore biomedical 2027 — contract research capacity and biotech IP commercialization

How many licensing deals has Singapore's national drug-discovery platform executed?

The national drug-discovery platform has executed close to 20 licensing deals across 25 corporate partners and more than 70 academic institutions (EDDC AR 2025), according to KIRA's 2026 market report.

Source: EDDC AR 2025, 2025 · KIRA report: Singapore biomedical 2027 — contract research capacity and biotech IP commercialization

How big is Singapore's biomedical manufacturing output, and where is it heading?

Biomedical manufacturing output is about S$43 bn in 2025 and is put near S$49 bn in 2027, from a S$38.1 bn base in 2023 (Kira estimates, according to KIRA's 2026 market report).

Source: Kira estimates, 2025 · KIRA report: Singapore biomedical 2027 — contract research capacity and biotech IP commercialization

How large is Singapore's national precision-medicine programme?

The programme entered its final phase in November 2025, enrolling about 10% of the resident population over five years to 2031, on top of 100,000 genomes already sequenced (NPM Phase III 2025), according to KIRA's 2026 market report.

Source: NPM Phase III 2025, 2025 · KIRA report: Singapore biomedical 2027 — contract research capacity and biotech IP commercialization

What tariff applies to branded finished pharmaceuticals entering the United States from Singapore?

Branded finished product entering the United States carries a 100% duty unless onshoring conditions are met, phased from 31 Jul 2026 (US Sec 232 2026), according to KIRA's 2026 market report.

Source: US Sec 232 2026, 2026 · KIRA report: Singapore biomedical 2027 — contract research capacity and biotech IP commercialization

How long does trial authorisation take in Singapore?

Trial authorisation runs about 30 working days and bioequivalence studies about 15, with ethics review in parallel (HSA CT 2025), according to KIRA's 2026 market report.

Source: HSA CT 2025, 2025 · KIRA report: Singapore biomedical 2027 — contract research capacity and biotech IP commercialization

More on Biomedical and biopharma in Singapore